Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 19/20 | 0.45 |
| ▸ | GNA15 | P30679 | 1/20 | 0.42 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 0.42 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.42 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.42 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10009995 | 0.88 | FFAR1 (0.39) | FFAR1PPARGPPARD | |
| SCHEMBL10011531 | 0.86 | FFAR1 (0.46) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL10011050 | 0.82 | FFAR1 (0.42) | FFAR1GNA15SLC10A1ABCC2SLCO1B3 | |
| SCHEMBL1707941 | 0.82 | PPARG (0.39) | FFAR1PPARGPPARD | |
| SCHEMBL1708167 | 0.82 | PPARG (0.39) | FFAR1PPARGPPARD | |
| SCHEMBL1708126 | 0.81 | FFAR1 (0.33) | FFAR1PPARGPPARD | |
| SCHEMBL1708666 | 0.80 | FFAR1 (0.37) | FFAR1PPARGPPARD | |
| SCHEMBL1708660 | 0.80 | FFAR1 (0.39) | FFAR1PPARGPPARD | |
| SCHEMBL1708672 | 0.80 | FFAR1 (0.39) | FFAR1PPARGPPARD | |
| SCHEMBL1707979 | 0.79 | PPARD (0.37) | FFAR1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | FFAR1 20/4885GNA15 845/4885SLC10A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.